JW67 inhibits canonical Wnt signaling with a ring IC50 of 1.17 μM. JW67 affects a multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1, which rapidly reduces active β-catenin and transcribes Wnt target genes. JW67 also inhibits colorectal cancer cell growth.

Physicochemical Properties

Molecular Formula	C21H18N2O6
Molecular Weight	394.377
Exact Mass	394.116
CAS #	442644-28-2
PubChem CID	644733
Appearance	Light yellow to yellow solid powder
LogP	1.846
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	0
Heavy Atom Count	29
Complexity	647
Defined Atom Stereocenter Count	0
InChi Key	BTXRSHKJNDFHGA-UHFFFAOYSA-N
InChi Code	InChI=1S/C21H18N2O6/c24-17-20(13-5-1-3-7-15(13)22-17)26-9-19(10-27-20)11-28-21(29-12-19)14-6-2-4-8-16(14)23-18(21)25/h1-8H,9-12H2,(H,22,24)(H,23,25)
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	JW67 (1 μM; 24 hours) lowers the active form of β-catenin and raises the concentration of AXIN2 [1]. Colon cancer cell line proliferation is inhibited and Wnt target gene expression is impacted by JW67 [1]. With a GI50 value of 7.8 μM, JW67 exhibits a concentration-dependent decrease in proliferation [1].
Cell Assay	Western Blot Analysis[1] Cell Types: SW480 Cell Tested Concentrations: 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: Increased AXIN2 expression. RT-PCR[1] Cell Types: SW480 cells Tested Concentrations: 10 or 25μM Incubation Duration: 72 hrs (hours) Experimental Results: diminished in vitro growth of SW480 CRC cells by inhibiting G1/S cell cycle progression.
References	[1]. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res. 2011;71(1):197-205.

Solubility Data

Solubility (In Vitro)

DMSO : ~50 mg/mL (~126.78 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 2.5 mg/mL (6.34 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.5356 mL	12.6781 mL	25.3563 mL
	5 mM	0.5071 mL	2.5356 mL	5.0713 mL
	10 mM	0.2536 mL	1.2678 mL	2.5356 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.